CONTACT
BUY

PREMOM Clinical Trial (completed)

Development and validation of the test

We have carried out a prospective multicentre clinical study that has made it possible to demonstrate the sensitivity and specificity of circulating cell-free RNA in the early screening of preeclampsia and other pregnancy complications.
ClinicalTrials.gov: NCT04990141

Study characteristics

14 participating hospitals

~9,600 pregnant women included

26,000 samples collected

Longitudinal design by trimester

Objectives
→ Development of a predictive model based on cfRNA
→ Identification of a molecular signature associated with preeclampsia

Result: development of MaiRa

From this clinical trial, the following has been achieved:

  • Identifying a patented cfRNA molecular signature
  • Developing a predictive algorithm based on artificial intelligence
  • Internally validating the model

This study has made possible the development of the first blood test for the early prediction of the risk of preeclampsia.

Validated pipeline

  • Blood sample processing
  • NGS sequencing
  • Transcriptomic profile
  • Risk prediction in the first trimester

Innovation and intellectual property

  • Patented cfRNA molecular signature
  • Proprietary predictive algorithm
  • Optimised laboratory protocol

Scientific publication

Results published in:

cfRNA as a predictor of preeclampsia

Nature Communications (2025)